Join to view full profile
6800 Pittsford Palmyra RdSte 150Fairport, NY 14450
Phone+1 585-364-1177
Fax+1 585-461-3509
Dr. Poligone is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterResidency, Dermatology, 2004 - 2007
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2003 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2008 - 2027
CT State Medical License 2007 - 2008
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2010 Jan 06
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
- Mechlorethamine Induced Contact Dermatitis Avoidance Study Start of enrollment: 2017 Dec 13
Publications & Presentations
PubMed
- Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor(Mechlorethamine) in the Treatment of CTCL.Brian Poligone, Christopher Pullion, Adam Rumage, Richard Straube, Oreola Donini
Oncology and Therapy. 2026-06-01 - Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma.James R Poligone, Priyanka Kadam, Elaine S Gilmore, Brian Poligone
Expert Opinion on Investigational Drugs. 2026-04-01 - Mycosis fungoides progression following COVID-19 mRNA vaccination: A case series.Priyanka Kadam, Manasi Ladrigan, Brian Poligone
JAAD Case Reports. 2026-04-01
Press Mentions
HyBryte™ Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOctober 7th, 2024- Soligenix Corporate Update Letter - Key Highlights and Upcoming CatalystsJanuary 10th, 2022
- Soligenix Anticipated to Achieve Multiple Milestones in 2021March 16th, 2021
Grant Support
- NF Kappa B Activity In Skin Inflammation And CarcinogenesisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
